Clinical Trial Update: CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

View source ↗

Summary

A Belgian registry study evaluating the use of vandetanib (Caprelsa) in current clinical practice for metastatic medullary thyroid carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Caprelsa (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Metastatic Medullary Thyroid Cancer | Status: COMPLETED